MX341309B - Anticuerpos especificos del heterodimero de anti-il-23. - Google Patents

Anticuerpos especificos del heterodimero de anti-il-23.

Info

Publication number
MX341309B
MX341309B MX2013000727A MX2013000727A MX341309B MX 341309 B MX341309 B MX 341309B MX 2013000727 A MX2013000727 A MX 2013000727A MX 2013000727 A MX2013000727 A MX 2013000727A MX 341309 B MX341309 B MX 341309B
Authority
MX
Mexico
Prior art keywords
specific antibodies
heterodimer specific
subunit
present disclosure
significantly bind
Prior art date
Application number
MX2013000727A
Other languages
English (en)
Other versions
MX2013000727A (es
Inventor
Pollard Matthew
William Clarke Adam
G Doyle Anthony
Tran Stephen
Original Assignee
Cephalon Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903234A external-priority patent/AU2010903234A0/en
Application filed by Cephalon Australia Pty Ltd filed Critical Cephalon Australia Pty Ltd
Publication of MX2013000727A publication Critical patent/MX2013000727A/es
Publication of MX341309B publication Critical patent/MX341309B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo aislado o recombinante, o un fragmento de unión al antígeno de este que se une específicamente a IL-23 caracterizado porque comprende: una CDR1 de cadena pesada que comprende la secuencia de aminoácidos de la SEC ID NO: 8; una CDR2 de cadena pesada que comprende la secuencia de aminoácidos de la SEC ID NO: 9 o 22; una CDR3 de cadena pesada que comprende la secuencia de aminoácidos de la SEC ID NO: 10; una CDR1 de cadena ligera que comprende la secuencia de aminoácidos de la SEC ID NO: 13; una CDR2 de cadena ligera que comprende la secuencia de aminoácidos de la SEC ID NO: 14; y una CDR3 de cadena ligera que comprende la secuencia de aminoácidos de la SEC ID NO: 15.
MX2013000727A 2010-07-20 2011-07-20 Anticuerpos especificos del heterodimero de anti-il-23. MX341309B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010903234A AU2010903234A0 (en) 2010-07-20 Anti-IL-23 heterodimeric specific antibodies
US38494510P 2010-09-21 2010-09-21
PCT/AU2011/000923 WO2012009760A1 (en) 2010-07-20 2011-07-20 Anti-il-23 heterodimer specific antibodies

Publications (2)

Publication Number Publication Date
MX2013000727A MX2013000727A (es) 2013-03-22
MX341309B true MX341309B (es) 2016-08-12

Family

ID=45496377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000727A MX341309B (es) 2010-07-20 2011-07-20 Anticuerpos especificos del heterodimero de anti-il-23.

Country Status (9)

Country Link
US (1) US9127057B2 (es)
EP (1) EP2596022A4 (es)
JP (1) JP5972871B2 (es)
CN (1) CN103108886B (es)
AU (1) AU2011282476B2 (es)
CA (1) CA2805653A1 (es)
MX (1) MX341309B (es)
NZ (1) NZ604415A (es)
WO (1) WO2012009760A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
RS55161B1 (sr) 2010-11-04 2017-01-31 Boehringer Ingelheim Int Anti-il-23 antitela
EP2844284A1 (en) 2012-05-03 2015-03-11 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
US9708401B2 (en) * 2012-05-22 2017-07-18 Bristol-Myers Squibb Company IL-17A/F cross-reactive monoclonal antibodies and methods of using the same
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
GB201214974D0 (en) * 2012-08-22 2012-10-03 Univ Edinburgh Avian proteins, nucleic acids and uses thereof
AU2014228553B2 (en) 2013-03-15 2019-01-24 Amgen Inc. Methods for treating Crohn's disease using an anti-IL23 antibody
EP2968500A4 (en) * 2013-03-15 2016-06-29 Univ Pennsylvania VACCINES WITH ONE ANTIGEN AND INTERLEUKIN-23 AS ADJUVANS
JP2016517408A (ja) 2013-03-15 2016-06-16 アムジェン インコーポレイテッド 抗ｉｌ−２３抗体を用いた乾癬の治療方法
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
BR112017004169A2 (pt) 2014-09-03 2017-12-05 Boehringer Ingelheim Int composto direcionado à il-23a e ao tnf-alfa e usos do mesmo
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
CA2998349A1 (en) 2015-09-17 2017-03-23 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
CA3003539A1 (en) * 2015-10-30 2017-05-04 Ablynx Nv Polypeptides against il-23
KR20180096633A (ko) 2015-12-22 2018-08-29 암젠 인크 Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20
IL267113B1 (en) * 2016-12-21 2024-05-01 Cephalon Llc Antibodies that bind specifically to human IL-15 and their uses
CN112689643A (zh) 2018-07-13 2021-04-20 阿斯特捷利康合作创业有限责任公司 用布雷库单抗治疗溃疡性结肠炎
CN109970855A (zh) * 2019-04-12 2019-07-05 深圳普瑞金生物药业有限公司 Il23单域抗体的vhh链、il23单域抗体、核苷酸序列及试剂盒
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
AU3691093A (en) 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
SG41929A1 (en) 1992-09-25 1997-08-15 Commw Scient Ind Res Org Target binding polypeptide
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US6291189B1 (en) 1994-05-10 2001-09-18 Carta Proteomics, Inc. Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6562622B1 (en) 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
EP1159611A1 (en) 1999-01-15 2001-12-05 Medtox Scientific Inc. Lateral flow test strip
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AU2002331408B2 (en) 2001-08-20 2008-05-08 Proteome Systems Ltd Diagnostic testing process and apparatus
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040265926A1 (en) 2002-11-21 2004-12-30 Leong Ng Bodily fluid markers of tissue hypoxia
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2525184C (en) * 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
CA2527726A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
WO2006102720A1 (en) 2005-03-31 2006-10-05 Telethon Institute For Child Health Research Isolation of inhibitor of ires-mediated translation
AU2006265002B2 (en) * 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
US7196172B2 (en) 2005-07-15 2007-03-27 Zymogenetics, Inc. Heterodimeric four helix bundle cytokines
KR20080068004A (ko) 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
MX2011001409A (es) * 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
MX2011002159A (es) 2008-08-27 2011-03-29 Schering Corp Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria.
AR074369A1 (es) 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof

Also Published As

Publication number Publication date
MX2013000727A (es) 2013-03-22
JP2013535191A (ja) 2013-09-12
US9127057B2 (en) 2015-09-08
CN103108886B (zh) 2016-08-24
CN103108886A (zh) 2013-05-15
AU2011282476B2 (en) 2015-08-20
CA2805653A1 (en) 2012-01-26
NZ604415A (en) 2014-10-31
JP5972871B2 (ja) 2016-08-17
AU2011282476A1 (en) 2013-01-10
EP2596022A1 (en) 2013-05-29
WO2012009760A1 (en) 2012-01-26
EP2596022A4 (en) 2014-11-05
US20130115166A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
PH12014502527A1 (en) St2 antigen binding proteins
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
EP4219552A3 (en) Il-11r binding proteins and uses thereof
WO2013188693A8 (en) Antigen binding constructs to cd3
MX357944B (es) Variantes anticuerpos y usos de las mismas.
MY162752A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
AU2009260320A8 (en) Antibodies to IL-6 and their uses
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
NZ720765A (en) Antibodies and methods of use
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
MX343659B (es) Proteínas de unión receptoras fc.
MX2010001237A (es) Nuevos anticuerpos.
WO2011085165A3 (en) Ca-125 immune complexes as biomarkers of ovarian cancer
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
MX343580B (es) Anticuerpos contra el g-csfr y sus usos.
WO2010136483A3 (en) Antigen-binding proteins
EP3773716A4 (en) MONOCLONAL ANTIBODIES THAT BIND TO SSEA4 AND THEIR USES
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
MX2021015473A (es) Nuevo anticuerpo específico para cthrc1 y su uso.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
PH12014502468A1 (en) Methods for identifying immunobinders of cell-surface antigens

Legal Events

Date Code Title Description
FG Grant or registration